Scarica l'app Stockscreener
1.55
3.73%
-0.06
Dopo l'orario di chiusura:
1.53
-0.02
-1.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.61
Aprire:
$1.62
Volume 24 ore:
1.84M
Relative Volume:
0.65
Capitalizzazione di mercato:
$154.66M
Reddito:
-
Utile/perdita netta:
$-37.34M
Rapporto P/E:
-1.1397
EPS:
-1.36
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
-2.52%
1M Prestazione:
-15.76%
6M Prestazione:
+22.05%
1 anno Prestazione:
+30.25%
Intervallo 1D:
$1.52
$1.66
Intervallo di 1 settimana:
$1.51
$1.67
Portata 52W:
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Nome
Sellas Life Sciences Group Inc
Settore
Industria
Telefono
(646) 200-5278
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Confronta SLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.55 | 160.64M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Iniziato | Oppenheimer | Outperform |
| 2018-04-02 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Aggiornamento | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
Sellas Life Sciences Reports Q2 2025 Financial Results - TipRanks
Sellas Life Sciences Group Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
SELLAS's AML Drug Triples Survival Rate in Phase 2 Trial, FDA Backs First-Line Treatment Study - Stock Titan
Sellas Life Sciences' GPS Trial Continues with Positive IDMC Recommendation - AInvest
SELLAS Life Sciences Receives Positive IDMC Recommendation to Continue Phase 3 REGAL Trial of GPS in AML. - AInvest
SELLAS Life Sciences Gets Positive IDMC Nod To Continue Phase 3 Trial Of AML Treatment - Nasdaq
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - The Manila Times
IDMC recommends continuation of Phase 3 AML trial for galinpepimut-S - Investing.com India
SELLAS Life Sciences Announces Independent Data Monitoring - GlobeNewswire
SELLAS Phase 3 Cancer Drug GPS Clears Critical Safety Review, Final Data Expected This Year - Stock Titan
SELLAS Life Sciences Group Inc. Consolidation Zone May Signal AccumulationMulti-Bagger Potential Stock Forecast Tools Released - metal.it
What institutional investors are buying SELLAS Life Sciences Group Inc. stockGet alerts on top growth stocks daily - Jammu Links News
What analysts say about SELLAS Life Sciences Group Inc. stockDiscover investment plans that deliver results - Jammu Links News
Does SELLAS Life Sciences Group Inc. stock perform well during market downturnsExceptional profit velocity - Jammu Links News
How does SELLAS Life Sciences Group Inc. compare to its industry peersBreakout stock performance - Jammu Links News
What are the latest earnings results for SELLAS Life Sciences Group Inc.Achieve fast wealth growth with smart picks - Jammu Links News
What are analysts’ price targets for SELLAS Life Sciences Group Inc. in the next 12 monthsRapid profit acceleration - Jammu Links News
What makes SELLAS Life Sciences Group Inc. stock price move sharplyGet professional advice for portfolio optimization - Jammu Links News
What are SELLAS Life Sciences Group Inc. company’s key revenue driversInvest smarter with daily stock recommendations - Jammu Links News
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised) - MSN
What is the dividend policy of SELLAS Life Sciences Group Inc. stockRetirement Planning Watchlist For Every Investor - Jammu Links News
What catalysts could drive SELLAS Life Sciences Group Inc. stock higher in 2025Wealth Building Trend Scanner For Smart Trading - Jammu Links News
Published on: 2025-07-31 14:02:06 - beatles.ru
Sector Leaders Rotate Capital Into SELLAS Life Sciences Group Inc.Stock Screener With Smart Filters Highlights Top Picks - beatles.ru
Published on: 2025-07-29 08:30:26 - metal.it
What risks could impact SELLAS Life Sciences Group Inc. stock performanceIntraday Trend Analysis for Fast Gains Released - beatles.ru
Should I hold or sell SELLAS Life Sciences Group Inc. stock in 2025Market Forecast Updates That Work - Jammu Links News
How strong is SELLAS Life Sciences Group Inc. company’s balance sheetFree Technical Analysis Support - jammulinksnews.com
How Resilient Is SELLAS Life Sciences Group Inc. Stock During Economic DownturnsTop Performer Shortlist - metal.it
SELLAS Life Sciences Group Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What institutions are buying SELLAS Life Sciences Group Inc. stock nowStrong return on assets - Jammu Links News
What drives SELLAS Life Sciences Group Inc. stock priceUnprecedented growth rates - PrintWeekIndia
Is SELLAS Life Sciences Group Inc. a good long term investmentExceptional profit potential - PrintWeekIndia
What drives USEA stock priceMassive wealth growth - Jammu Links News
Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):